Alcoholic steatohepatitis

Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):683-93. doi: 10.1016/j.bpg.2010.07.003.

Abstract

Severe alcoholic steatohepatitis has a poor prognosis and is characterized by jaundice and signs of liver failure. Its incidence is unknown, but prevalence is around 20% in cohorts of alcoholics undergoing liver biopsy. Diagnosis is established with elevated liver transaminases, neutrophil counts, serum bilirubin, and impaired coagulation and a history of excessive alcohol consumption, and exclusion of other etiologies. Histology is helpful but not mandatory. Prognostic scores include the Maddrey's discriminant function, the model of end-stage liver disease, and the Glasgow Alcoholic Hepatitis Score. Pathophysiology involves hepatic fat storage, increased hepatic uptake of gut-derived endotoxins triggering Kupffer cell activation and release of proinflammatory triggers, induction of cytochrome P4502E1 producing toxic acetaldehyde and reactive oxygen species, and ethanol-mediated hyperhomocysteinemia causing endoplasmic reticulum stress. Treatment includes abstinence, enteral nutrition, corticosteroids, and possibly pentoxifylline. A debate is ongoing whether certain patients with severe alcoholic steatohepatitis could be eligible for liver transplantation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cytochrome P-450 CYP2E1 / physiology
  • Enteral Nutrition
  • Fatty Liver, Alcoholic* / diagnosis
  • Fatty Liver, Alcoholic* / pathology
  • Fatty Liver, Alcoholic* / physiopathology
  • Fatty Liver, Alcoholic* / therapy
  • Glucocorticoids / pharmacology
  • Glucocorticoids / therapeutic use
  • Health Status Indicators
  • Humans
  • Lipid Peroxidation
  • Liver / pathology
  • Liver Transplantation
  • Prognosis
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Glucocorticoids
  • Tumor Necrosis Factor-alpha
  • Cytochrome P-450 CYP2E1